Therefore, future studies should control for standardized assays for measuring IGF-1 levels, have repeated assessments, and elucidate the relationship between peripheral and central nervous system levels of this factor in MDD patients and healthy controls. The gene discussed is IGF1; the disease is major depressive disorder.